~" In vivo experiments on the vasoactive effects of vasopressin and oxytocin on cerebral circulation were carried out in anesthetized dogs, using an electromagnetic flowmeter to measure vertebral blood flow and angiography to measure the internal diameter of the basilar artery. Direct bolus infusion of 1 pmol to 1 nmol of vasopressin or 10 pmol to 10 nmol of oxytocin into a femoral-vertebral artery shunt produced a dosedependent decrease in vertebral artery blood flow without significantly affecting mean arterial blood pressure. Vasopressin was more potent than endothelin and neuropeptide Y, which have also been demonstrated to induce long-lasting decreases in vertebral artery blood flow. However, direct bolus infusion of vasopressin (100 pmol and I nmol) or oxytocin (1 nmol and 10 nmol) into the vertebral artery dilated major vessels including the vertebral, anterior spinal, and basilar arteries, as well as the circle of Willis and its main branches, while endothelin (1 nmol) and neuropeptide Y (5 nmol) caused no change in the diameters of major cerebral arteries. The V~ antagonist d(CH2)5tyrosine(methyl) arginine vasopressin suppressed the effects of both vasopressin and oxylocin. Vasopressin was over 10 times as potent as oxytocin in both assays. The vasodilatory effect of vasopressin, which may be mediated by an endothelium-dependent mechanism, was functionally damaged in dogs after experimental subarachnoid hemorrhage. These data suggest regional differences in the sensitivity and responsiveness of vasculature to vasopressin and oxytocin, and specifically that both peptides act through V~ receptors to decrease the resistance of large vessels and increase the resistance of small vessels.
V
ASOPRESSIN and oxytocin, circulating hormones released from the neurohypophysis, are potent vasoconstrictors in a variety of peripheral vascular beds 3'39 and have been implicated in several forms of hypertension/'6'7 However, their hemodynamic influences on cerebral circulation seem to be complex and are not yet accurately understood. Many in vitro and in situ studies have shown that administration of vasopressin markedly constricted cerebral arteries in several species, including humans, goats, rabbits, and cats, 25'26'31'39 but also that it was capable of producing endothelium-dependent relaxation of the canine basilar artery, 17,18 while lysin vasopressin had no influence on the diameter of rat pial arterioles. 2-' Most studies in 1;ivo, 12'19'24 '25 like those performed in vitro and in situ, do not provide consistent evidence, and circulating vasopressin has been found to cause both increased and decreased cerebral blood flow (CBF). Faraci, et al., j2 suggested that one likely explanation for this lack of agreement was that cerebral vasculature displays regional differences in responsiveness to vasopressin, and they specifically found that vasopressin decreased the resistance of large pial vessels, but increased the resistance of small pial vessels without influencing the total CBF in cats.
Although two types of vasopressin receptors (V~ and V2) have been reported, 28 the identity of the vasopressin receptors present in the cerebral circulation has not been defined clearly. It is known that V~ receptors activate inositol phosphate turnover and calcium mobilization ~ and inhibit adenylate cyclase in rat aortic smooth muscle, 32 whereas V2 receptors coupled to adenylate cyclase induce an increase in cyclic adenosine monophosphate accumulation and water permeability of renal collecting duct cells. 2'28 It has already been suggested that both vasopressin and oxytocin cause contraction and endothelium-dependent relaxation by activating V~-vasopressinergic receptors,~6,~7 but intracarotid ad-ministration of a V2 agonist in rats increased CBF, with increased cerebral oxygen consumption and decreased cerebral vascular resistance/9 Different distributions and sensitivities of these receptors may explain the heterogeneity of the response to vasopressin by the cerebral circulation.
The purpose of this study was to examine regional differences in the cerebral vasoactivity of vasopressin and oxytocin using two in vivo methods. Experiments were carried out in anesthetized dogs, using an electromagnetic flowmeter to measure vertebral artery blood flow and angiography to investigate effects on the internal diameter of the basilar artery. Possible alterations in the vasoactive effects of these peptides in pathological conditions were further investigated using a canine model of subarachnoid hemorrhage (SAH),
Materials and Methods

Measurements of Vertebral Artery Blood Flow
Mature mongrel dogs, each weighing 8 to 20 kg, were anesthetized with pentobarbital (20 to 30 mg/kg) intravenously, intubated through the trachea, and ventilated with room air delivered by a respirator. The ventilation rate (15 cycles/rain) and tidal volume (20 ml/kg) were adjusted to maintain arterial blood gas levels and pH within physiological limits. In this series, the mean value (+ standard error of the mean) of pO2 was 105.0 _ 8.0 mm Hg, of pCO2 was 36.8 + 1.9 mm Hg, and of pH was 7.414 _+_ 0.023. A catheter was placed in the left femoral artery to monitor mean arterial blood pressure and heart rate. To prevent dehydration, which induces elevation of endogenous plasma vasopressin, a slow intravenous infusion of saline was maintained during the procedures.
Vertebral artery blood flow was determined using a short extracorporeal loop constructed between the femoral and vertebral arteries. An electromagnetic flow probe* was used to measure blood flow from the femoral to the vertebral artery in the extracorporeal fistula. Peptides were infused into the femoral-vertebral arterial loop in 0.05 ml physiological saline over 5 seconds. Heparin sodium (1000 U/kg) was administered intravenously to prevent coagulation.
The percentage change in vertebral artery blood flow was calculated by the following equation, as described previously: 5'4' 37 % change = (postdose blood flow/predose blood flow -1) • 100.
Measurement of Vascular Diameter by Angiography
The internal diameter of the basilar artery was determined by vertebral angiography in dogs under general anesthesia with intravenous pentobarbital. Respiration was controlled via an endotracheal tube. For vertebral angiography, a catheter was inserted directly into the * Electromagnetic flow probe, Model MFV-1100, manufactured by Nihon Kohden Co., Tokyo, Japan.
right vertebral artery at the base of the neck. Angiography at fixed magnification using 3 ml of 65% iothalamate meglumine was performed periodically after peptides were infused into the vertebral artery in 2.0 ml of physiological saline over 5 seconds. Diameters of the basilar arteries were measured using a computerized image analysis system t and were compared to determine the effects of the peptides on vascular activity. It was also verified that no muscular branches were present distal to the catheterization site on the vertebral artery.
Experimental Subarachnoid Hemorrhage
Experimental SAH was produced as detailed elsewhere. '3,38 Briefly, fresh autologous blood (5 ml) was injected into the cisterna magna of experimental animals on Day 1 and on Day 3. All procedures were performed with the animals under general anesthesia with intravenous pentobarbital. We have previously confirmed that this model of SAH consistently produces angiographically proven chronic cerebral vasospasm.~3'38 Vasopressin~ was injected after a single intracisternal injection of autologous blood at 1 hour and on Day 2 and after double injections of blood on Days 4 and 7.
Statistical Analysis
All data are expressed as means _ standard error of the means. Differences were compared utilizing Dunnett's multiple range test and paired t-test. P values of less than 0.05 were considered significant.
Results
Vertebral Artery Blood Flow
After a single infusion of vehicle (saline solution) into the femoral-vertebral artery shunt, vertebral artery blood flow remained stable (24.3 + 2.0 to 23.1 + 1.9 ml/min) for 10 minutes. Direct bolus administration of 1 pmol to 1 nmol of vasopressin produced a dosedependent decrease in vertebral artery blood flow ( Fig.  1 left) . For example, the decrease in vertebral artery blood flow caused by a l-nmol infusion of vasopressin was maximum at 2 minutes (37.2% + 4.4% of control) and remained depressed for more than 10 minutes. No appreciable changes in mean arterial blood pressure occurred during vasopressin administration ( Table 1) . Administration of 10 pmol to 10 nmol of oxytocinw produced a similar dose-dependent decrease in vertebral artery blood flow ( Fig. 1 right) . Vasopressin was over 10 times as potent as oxytocin in this assay.
t Macintosh Ilcx computer manufactured by Apple Computer, Inc., Cupertino, California; Image 1.27 software supplied by National Technical Information Service, Springfield, Virginia.
z~ Synthetic vasopressin (Arg-vasopressin) obtained from Peptide Institute, Inc., Osaka, Japan.
w Oxytocin obtained from Peptide Institute, Inc., Osaka, Japan. 
Angiography on Intact Dogs
Direct bolus administration of vasopressin (100 pmol and 1 nmol) or oxytocin (1 nmol and 10 nmol) into the vertebral artery dilated the major arteries including the extra-and intracranial vertebral, anterior spinal, and basilar arteries, and the circle of Willis and its main branches (Figs. 3 and 4) . The middle portion of the basilar artery was chosen for quantitative assessment by computerized image analysis of the changes after administration of vasopressin or oxytocin. The maximum dilatation induced by a 1-nmol infusion of vasopressin 
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was more than 150% of control at 2 minutes, and significant dilatation persisted for 20 minutes. Oxytocin also significantly dilated the basilar arteries, but the magnitude of dilatation was clearly less than that by vasopressin. Oxytocin also had similar effects on the other vessels mentioned above.
Whether the dilatation induced by vasopressin was mediated through V~ receptors was investigated using a V, antagonist (Fig. 5) . Simultaneous administration of 10 nmol of V1 antagonist and 1 nmol of vasopressin completely inhibited the dilatation of the basilar artery caused by 1 nmol of vasopressin. The V~ antagonist alone did not produce any measurable change in the diameter of the basilar artery.
In order to compare the effects of vasopressin and oxytocin on vertebral artery blood flow and on the vascular diameter of large vessels, the maximum effects of each concentration were plotted in Fig. 6 . The decrease in vertebral artery blood flow caused by vasopressin and oxytocin started at approximately one-tenth the concentration of that needed to cause dilatation of large arteries. Vasopressin was more than 10 times as active as oxytocin in both assays. Endothelin (1 nmol) and neuropeptide Y (5 nmol),* which also are known to produce a long-lasting decrease in vertebral artery blood flow, 36'37 did not induce any appreciable changes in the diameters of large arteries on angiography. Similar results for endothelin measured by angiography have been reported previously in cats and dogs. 29 
Angiography in Dogs After Subarachnoid Hemorrhage
Experimental SAH induced vasospasm of large cerebral arteries, especially after a second intracisternal injection of blood on Day 3 (Fig. 7) . The mean diameter of basilar arteries measured on angiography was 63.9% + 1.8% of control on Day 4 and 57.8% _+ 5.2% of control on Day 7. The influence of experimental SAH on vasopressin-induced vasodilation was investigated by angiography (Fig. 8) . The dilatation caused by 1 nmol vasopressin was suppressed from 1 hour after the first injection of blood on Day 1. The basilar artery on Day 4 showed a slight contraction instead of dilatation 2 minutes after the administration of vasopressin; however, the response of the basilar artery to vasopressin apparently recovered by Day 7.
Discussion
Regional Differences
These results in anesthetized dogs showed that direct infusion of vasopressin or oxytocin into the vertebral artery produced a decrease in vertebral artery blood flow without any obvious accompanying effects on systemic arterial blood pressure. However, when these peptides were infused into the vertebral artery, they * Endothelin-1 and neuropeptide Y obtained from Peptide Institute, Inc., Osaka, Japan. dilated the major cerebral arteries, especially the extracranial and intracranial vertebral, the anterior spinal, and the basilar arteries, as well as the circle of Willis and its main branches. This discrepancy suggests that the decrease in vertebral artery blood flow reflects increased resistance in the smaller arteries and arterioles supplied by the vertebral artery. Both endothelin and neuropeptide Y also caused long-lasting decreases in vertebral artery blood flow, but these peptides did not induce any changes in the diameters of major cerebral vessels measured by angiography. The measured vertebral artery blood flow (which also includes extracranial contamination reflecting flow changes in skeletal muscle and meninges, for example) was probably more affected by the response of the microvasculature than that seen in the large vessels on angiography. Using different methods in cats, Faraci, et al., ~z have also reported that there are regional differences in the response of the cerebral circulation to vasopressin, specifically that vasopressin decreases the resistance of large vessels but increases the resistance of small vessels. In support of the above hypothesis, we recently confirmed, using the in vitro method of Dacey and Duling, 8 that the main response to vasopressin of rat intracerebral (parenchymal) arterioles of 50-urn average diameter was vasoconstriction (data not shown). Oxytocin was less potent than vasopressin in both vasodilation and vasoconstriction.
Endothelium Relaxation
A possible mechanism by which vasopressin and oxytocin induce vasodilation in large cerebral arteries has been suggested previously. Vasodilation is probably mediated through the endothelium rather than through neurogenic or metabolic regulation, as has been shown in the canine basilar artery in vitro. 16-~8 The endothelium-dependent relaxation caused by both vasopressin and oxytocin was strong, almost identical in magnitude to that induced by papaverine, and it was completely inhibited by removal of the endothelium or addition of a V:vasopressinergic antagonist.~6'~7 These in vitro data are quite consistent with our in vivo data in both the magnitude of vasodilation and the ability of a Vj antagonist to inhibit vasodilation. Our recent studies demonstrated that intracisternal administration of NG-monomethyl-L-arginine (an arginine analogue that inhibits enzyme formation of NO) suppressed the vasodilation produced by vasopressin infused into the vertebral artery (data not shown). This evidence also supports the endothelium-dependent vasodilatory mechanism. In addition to vasopressin, oxytocin is known to exert its vasorelaxant as well as its vasoeontractile activity as an agonist at the vascular V~ receptor) 6 The vasodilation produced by vasopressin and oxytocin was notable for its long duration.
V2 Receptors
Another possible mechanism for the vasodilation of cerebral arteries induced by vasopressin may be medi- ated through V2 receptors, as it is in the peripheral circulation. 23.33:~ High doses of V2 agonists are known to cause an increase in CBF, with increased cerebral oxygen consumption, ~9 which may be related to the indirect vasodilatory influence of vasopressin through an increase in the metabolism of vasopressin-sensitive neuronal systems 21 or in the permeability of microvessels. 2~ In this study, simultaneous administration of 100 pmol of vasopressin and 10 nmol of V~ antagonist slightly increased vertebral artery blood flow with n o change in the large vessel diameter, suggesting the possibility of V2 receptor-mediated vasodilation in the smaller vasculature not seen by angiography. The small vessel vasoconstriction from vasopressin alone suggested above is probably due to a predominating V~ (constrictive) effect over a V2 (dilatory) effect.
Plasma and Cerebrospinal Fluid Levels
Certain pathological conditions, ':7'354' including hemorrhage, dehydration, or SAH, have been observed to lead to a rise in plasma and cerebrospinal fluid (CSF) levels of vasopressin. In fact, Mather, et at., 27 reported that patients with SAH who were in poor clinical condition had increased concentrations of plasma and CSF vasopressin. Recent experiments have suggested that an increased release of vasopressin into the CSF was involved in the development of acute cerebral vasospasm after SAH. 9 In our study using a canine model of SAH, circulating vasopressin lost its ability to dilate the large cerebral arteries immediately after SAH and began to recover by Day 7. A slight vasocontraction instead of vasodilation of the basilar artery occurred after the administration of vasopressin on Day 4. This suggests that functional damage to the vascular endothelium may start from the beginning of SAH, if we assume that the vasodilation caused by vasopressin is related to the endothelium. Several pharmacological studies in vitro '8"3~ have demonstrated that vasodilation mediated through the endothelium was severely impaired after SAH. Our data also suggest that vasopressin functions as a pure vasoconstrictor in SAH, which may well worsen acute and chronic vasospasm by decreasing global CBF.
Recently, vasopressin-immunoreactive nerve fibers have been demonstrated in the cerebral pial arteries of the guinea pig. '5 If vasopressinergie nerve fibers are present in the cerebral vascular walls in all animals, neural delivery as well as vascular delivery may be involved in the physiological effects of vasopressin and oxytocin on the cerebral circulation. Interaction of intraluminal and extraluminal vasopressin from different origins could contribute to the adjustment of local CBF. Although the doses of vasopressin and oxytocin employed in our experiments seem to be nonphysiologically high compared to those detected in normal plasma and CSF, 10,41 it is very likely that these peptides have similar, though smaller, effects at lower concentrations or that peptides are concentrated locally (for example, by neural delivery) to adjust local vascular tonus. The precise physiological role of these peptides in the regulation of CBF remains to be defined, but our present results strongly suggest that vasopressin and oxytocin may function through V1 receptors both to vasoconstrict and to vasodilate.
